Regional Emergency Medical Advisory Committee
431 New Karner Road • Albany, NY 12205
Office 518.464.5097 • Fax 518.464.5099
www.remo-ems.com

ADVISORY: 2016 – 02

DATE: November 16, 2016

Re: MAD recall by Teleflex – Intranasal medication delivery

Attachment: Teleflex recall notice, DOH letter of notification

This advisory pertains to the notifications from Teleflex and the Department of Health that are attached. Please realize, that our first and foremost concern must always be the best outcomes for our patients. The regional and statewide law-enforcement and basic life support first response naloxone programs have been a resounding success. The opioid crisis does not show any signs of letting up, in fact with the advent of new synthetic opioids there is even more risk to public health.

Is important to recognize that the mucosal atomizers are recalled because they may fail to appropriately atomize medication as expected. While there will be no injury to the patient from the use of the device, the medication delivery may not be as efficient. This does not mean that medications administered will not work. In fact, medications were administered intranasally prior to the advent of the MAD device. Given this, in consultation with the New York State Department of Health as well as toxicology experts and other emergency physicians, we make the following recommendations:

- All patients who to whom medications are administered intranasally should be monitored carefully to assure the medications are as effective as intended.
- All naloxone kits that are currently deployed should remain in service.
- Any concerns about the efficacy of naloxone should be reported when documented.
- All responders utilizing intranasal naloxone should be prepared administer additional doses of naloxone and to assist with ventilations as necessary.
- Any mucosal atomizers that are not yet in-service should be checked for lot number and replaced through the vendor if appropriate.